Prostate Cancer Clinical Trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Summary

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male ≥18 years of age at the time of signing informed consent
Histologically or cytologically confirmed adenocarcinoma of the prostate
Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible
Adequate organ function

Exclusion Criteria:

Prior solid organ transplant
Prior treatment with PSMA-targeted CAR-T cell therapy
Clinically significant cardiovascular disease
Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other)
Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT05519449

Recruitment Status:

Recruiting

Sponsor:

Janux Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco California, 94158, United States More Info
Sarah Cannon Research
Nashville Tennessee, 37203, United States
Mary Crowley Cancer Research
Dallas Texas, 75230, United States
Chris O'Brien Lifehouse (COBLH)
Camperdown New South Wales, 2050, Australia
Southern Oncology Clinical Research Unit (SoCRU)
Bedford Park South Australia, 5042, Australia
Linear Clinical Research Ltd.
Nedlands Western Australia, 6009, Australia

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT05519449

Recruitment Status:

Recruiting

Sponsor:


Janux Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.